---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-053075"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:04:30.327226+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics Q1 net loss $2.5M; details Phase 3 plan for CAD-1005 in HIT

## Summary
- Net loss $2.5M in Q1 2026 vs $3.8M in Q1 2025; operating expenses $2.5M vs $3.9M.
- Cash $2.3M at March 31; subsequent $2.5M financing completed April 1, 2026.
- Received FDA EOP2 meeting minutes; plans randomized, blinded, placebo-controlled Phase 3 trial in ~120 HIT patients.
- Phase 2 data showed >25% absolute reduction in thrombotic events with CAD-1005 added to standard anticoagulant therapy.
- CAD-1005 is first-in-class 12-LOX inhibitor; holds FDA Orphan Drug and Fast Track designations.

## SEC filing metadata
- accession: 0001213900-26-053075
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390026053075/0001213900-26-053075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390026053075/ea0289377-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-053075
- JSON: https://secwatch.observer/filing/0001213900-26-053075.json
- Plain text: https://secwatch.observer/filing/0001213900-26-053075.txt

## Source-grounded claims
- claim_id: 89d00ab5080dd990e2106ab8c3c1e75fbcf95ca7
  claim: Cadrenal Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $2.5 million.
  evidence_excerpt: Cadrenal reported a net loss of $2.5 million for the quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390026053075/0001213900-26-053075-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.